HYDRALYTE_1170x120

guanfacine extended-release tablets

Impax cleared to market Intuniv generic

Impax cleared to market Intuniv generic

HAYWARD, Calif. — Impax Laboratories Inc. has received approval from the Food and Drug Administration for guanfacine extended-release tablets, a treatment for attention deficit hyperactivity disorder (ADHD). Impax said late Wednesday that its guanfacine ER product, a generic version of Intuniv from Shire, comes in strengths of 1 mg, 2 mg, 3 mg and 4

Mylan, Teva roll out generic versions of Intuniv

Mylan, Teva roll out generic versions of Intuniv

NEW YORK — Mylan N.V. and Teva Pharmaceutical Industries Ltd. have released guanfacine extended-release tablets, a nonstimulant medication for attention deficit hyperactivity disorder (ADHD), in the United States. The pharmaceutical companies said Tuesday that their products, available in strengths of 1 mg, 2 mg, 3 mg and 4 mg, are generic equivalents of Intuniv from